Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like the games to frustrate longs will continue today. however the company announcements continue to be outstanding and thats all I really care about
Where's that biopsy req??? Lmao
Well said. While none of us Ariad investors knew for sure that the company would be bought for over 5 billion we jumped in post crash after extensive DD about the pipeline. Many of us smartly invested without all the whining and moaning kicking and screaming that folks like 2Da did...I never wrote extensive letters to the board, became litigious, nor did I have to waste all that energy that someone like he did during those years. We all ended up at the same price of $24. even without a buyout the prospects of brig approval are strong and as I mentioned previously we can expect to hear its FDA fate before EOM.
wasn't there a 90 day lock-up for folks associated with buying the shares at the PO?
interesting I didn't know Paris joined medicines co. I'll have to read about that. its been on my watchlist though. I bet they announce Brig's fate soon hopefully not half hour prior to the PDUFA deadline but you never know
I think there are hanging around. by the way we should be hearing about brigatinib pretty soon
I did miss it!
Whoa
Ahhhh the ariad board is back baby
nice add!
haha. no way... theres no ichmoto cloud on that forecast
You certainly arenot Rachel 3.90's would be way above her estimates.
amen to that.
also many biotechs recently had offerings at big discounts to closing prices. see dews board for some recent announcements. auph is in great shape
the 150ish employees will easily find jobs in that market, especially the biotech legal folks lol
thinking of adding more BR?
GW Pharmaceuticals Announces Epidiolex® Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Lennox-Gastaut Syndrome
http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=1019184
Jess well said. the only reaction I had to this day's action and article was to add 2k shares at 6.75 as previously noted. AUPH is great
Added 2k at 6.75. Glta
haha yes very very familiar stuff.
I'm actually interested in what Adam would say about this critique article as he has been supportive of AUPH so far since the rise to the offering. If this continues to drop to the offering price I'm prepared to add,. I wonder if it will drop below the offering price, bet those big boys who bought loads at 6.75 would be pissed.
biotech isn't boring for sure!
hahaha.
I think we will soonly see that AUPH has a lot of leverage considering voclosporin exclusivity, its efficacy, its science...I'm so confident in my DD that I will leave soonly in my response as a real word. Must be trumps influence.
seriously, there will be catalysts on the way. in the form of BP interactions and negotiations. IMO
TESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast Cancer
http://ir.tesarobio.com/releasedetail.cfm?ReleaseID=1018917
TSRO FDA early approves Niraparib (ZEJULA)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf
yes the data that was released at 3:30am today was impressive along with the rest of the studies so far. Voclosporin is a winner and glickman will remain busy fielding early offers and strategies from BP IMO. Its reasonable at this time to assume that the Ph3 trial could be a candidate for early termination due to safety and efficacy so that patients can access this medicine sooner rather than later since there have already been two distinct 48 week data endpt exceeds
GLTA
AURION48 week data
MARCH 27, 2017
-Biomarkers of disease activity at eight weeks can predict renal response at 24 and 48 weeks
http://ir.auriniapharma.com/press-releases/detail/81
they started last year :
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 29, 2016) - Cheoin Leisure Co., Ltd. (the "Acquiror") is pleased to announce that it has acquired 1,694,915 units (the "Units") of Aurinia Pharmaceuticals Inc. ("Aurinia") under a previously announced private placement (the "Private Placement") at US$2.36 per Unit which, based on the June 22, 2016 Bank of Canada closing exchange rate of CDN$1.2839 per U.S. dollar, equals CDN$3.03 per Unit. Each Unit comprises one common share ("Common Share") in the capital of Aurinia and 0.35 of a Common Share purchase warrant (each whole such warrant, a "Warrant"), each such Warrant entitling the holder to purchase one Common Share.
Prior to the Private Placement, the Acquiror held nil Common Shares and Warrants representing 0% of the issued and outstanding Common Shares. After the Private Placement, the Acquiror holds 1,694,915 Common Shares and 593,220 Warrants representing beneficial ownership and control of 4.80% of the issued and outstanding Common Shares on a non-diluted basis and 5.05% of the outstanding Common Shares on a fully diluted basis.
Depending on market conditions and regulatory requirements, the Acquiror may from time to time increase or decrease its beneficial ownership, control or direction over any of Aurinia's securities through market transactions, private agreements or otherwise. The Acquiror also announces that it has filed Form 62-103F1 - Required Disclosure Under the Early Warning Requirements as a result of its acquisition under the Private Placement, a copy of which can be obtained on Aurinia's SEDAR profile at www.sedar.com or by contacting the Acquiror.
thank you for sharing this TC. very interesting model.
Vid and Lunacy- thank you for your responses, my concerns about a PR not being issued about AURION. 48wk data have dropped big time. I did some digging in IR and found that at AURION 24wk data PR was issued in synch with Huizinga's presentation of the respective data at the Lupus Conference which at that time was held in Venice Italy on October 6th 2016. So shareholders who were waiting on that data had to wait for Robert's presentation then too. So the company is being consistent with the AURION48wk data announcements with not issuing a PR prior to the presentation.
Looking forward to reading about the data update on monday
GLTA
I surprised they didn't PR anything about the 48wk Aurion data that will be presented Monday in Australia. do you find that odd or just how they want it to unfold. I have heard some chatter that a PR will be posted on AUPH's IR page following the presentation in Australia and again that too sounds odd.
so far all of the data released by the company has been super impressive. and I don't want to sound like I'm reading into the drama of when they should release a PR about data, but since we won't get a live feed from down under to listen in at 3AM EST, shouldn't they PR something prior, and today would have been that day considering the schedule of events?
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 March 2017--->6 medicines (3 orphans) recommended for approval
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/03/news_detail_002712.jsp&mid=WC0b01ac058004d5c1
On 6 March 2017, PTC Therapeutics International Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for Translarna to be used to treat cystic fibrosis.
http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2017/03/WC500224384.pdf
FDA Approves Symproic® (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
SHIONOGI/Purdue Pharma
http://www.businesswire.com/news/home/20170323006354/en/FDA-Approves-Symproic®-naldemedine-Once-Daily-Tablets-C-II
You beat me to the post w/ same link by 2 min. Congrats :)
I am eagerly awaiting the corporate plan update regarding the bold portion!
'These factors raise substantial doubt about our ability to continue as a going concern within twelve months following the date of the filing of this Form 10-K. Our ability to continue as a going concern and finance operations beyond our current resources will depend heavily on value investors see in the data from our previous clinical trials of OCR-002 and favorable results from any future clinical trials of OCR-002 we may conduct. We plan to raise additional capital through collaboration, licensing or similar arrangements, private and public equity offerings or debt financing, or a combination thereof. Additional financing may not be available when we need it or may not be available on terms that are favorable to us. Collaboration, licensing or similar arrangements may require us to relinquish valuable rights to our potential products or proprietary technologies. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of existing stockholders. '
agreed
anyone have any input on Ocera's ability to fundraise this year to pay for the needed trials? I think there is a lot of potential here in the pipeline, and based on the recent presentation, however funding and dilution are definite headwinds. thoughts?
TC- you are stuck in aria mode!
I wonder what to expect from the 48 wk aurion data. we finally got to see the 48 week aura data update and so much has happened since that PR including a massive successful fundraising effort for the next phase. Just curious about this batch of data that is traveling all the way to Australia for us to see.
I think you are correct in that some sort of offering will have to occur in the future to assist with the funding of the needed trials. however with the price struggling in this range it will be a challenge. Also today is just a poor day system wide. some of the losses today are a bit overkill. What are you thoughts about fundraising in 2017 BR?